Esperion Investor Day: Lighting the Way for Phase 2b Results

September 5, 2014
Tim Mayleben
President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day event that included presentations from several of the world’s leading experts in their respective fields.  It was an exciting and informative day! Dr. James McKenney, President and CEO of National Clinical Research, and Professor Emeritus… Read More

Reflections One Year Post-IPO

June 26, 2014
Tim Mayleben
President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More

Posted In: Company News

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

May 19, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer
Marianne Andreach
Vice President, Strategic Marketing & Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited any time there is a specific emphasis on, or a new development in, this underserved patient population. In the… Read More

Working to Impact the Lives of Millions of Statin Intolerant Patients

November 11, 2013
Tim Mayleben
President and Chief Executive Officer

I re-joined Roger at Esperion almost a year ago to help people who are at risk for debilitating and life-threatening heart attacks and strokes because they have elevated levels of LDL-C (the bad cholesterol), but who are unable to take a statin because of myalgia (muscle pain). These patients are considered statin intolerant – and… Read More

Posted In: Company News

Getting the Band Back Together

August 8, 2013
Tim Mayleben
President and Chief Executive Officer

Late last year, one of the country’s most brilliant scientists called me and asked if I wanted to help him change the lives of millions of people – again. Two decades ago, that scientist, Roger Newton, helped create the statin Lipitor, which turned out to be the best selling pharmaceutical drug of all time. Because… Read More